Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Tax Provisions: 2009-2025

Historic Tax Provisions for Gyre Therapeutics (GYRE) over the last 6 years, with Sep 2025 value amounting to $1.7 million.

  • Gyre Therapeutics' Tax Provisions rose 57.64% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 32.92%. This contributed to the annual value of $6.3 million for FY2024, which is 32.38% down from last year.
  • As of Q3 2025, Gyre Therapeutics' Tax Provisions stood at $1.7 million, which was up 155.74% from $662,000 recorded in Q2 2025.
  • Gyre Therapeutics' Tax Provisions' 5-year high stood at $6.0 million during Q4 2022, with a 5-year trough of $662,000 in Q2 2025.
  • Moreover, its 3-year median value for Tax Provisions was $1.5 million (2023), whereas its average is $1.7 million.
  • As far as peak fluctuations go, Gyre Therapeutics' Tax Provisions tumbled by 74.40% in 2023, and later surged by 57.64% in 2025.
  • Over the past 4 years, Gyre Therapeutics' Tax Provisions (Quarterly) stood at $6.0 million in 2022, then plummeted by 74.40% to $1.5 million in 2023, then declined by 21.40% to $1.2 million in 2024, then soared by 57.64% to $1.7 million in 2025.
  • Its Tax Provisions was $1.7 million in Q3 2025, compared to $662,000 in Q2 2025 and $901,000 in Q1 2025.